Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD3759 |
Synonyms | |
Therapy Description |
AZD3759 inhibits EGFR, potentially resulting in decreased growth of EGFR-expressing tumors and is also able to fully penetrate the blood-brain barrier (PMID: 27928026, PMID: 29430654). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD3759 | AZD-3759|zorifertinib | EGFR Inhibitor (Pan) 62 | AZD3759 inhibits EGFR, potentially resulting in decreased growth of EGFR-expressing tumors and is also able to fully penetrate the blood-brain barrier (PMID: 27928026, PMID: 29430654). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02228369 | Phase I | Osimertinib AZD3759 | Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM) | Completed | USA | AUS | 2 |